Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

ESCC × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 37 Carcinoma, Non-Small-Cell Lung 26 Triple Negative Breast Neoplasms 21 Stomach Neoplasms 20 Nasopharyngeal Carcinoma 19 Esophageal Neoplasms 18 Esophageal Squamous Cell Carcinoma 16 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Colorectal Neoplasms 11 Uterine Cervical Neoplasms 10 Pancreatic Neoplasms 8 Lung Neoplasms 8 Sarcoma 7 Recurrence 7 Neoplasm Metastasis 7 Melanoma 6 Liver Neoplasms 6 Hodgkin Disease 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Advanced Gastric Cancer 5 Small Cell Lung Carcinoma 4 Neoplasms 4 Locally Advanced Gastric Cancer 4 Solid Tumor 3 Rectal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Osteosarcoma 3 Nasopharyngeal Neoplasms 3

Interventions

trifluridine tipiracil drug combination 1 camrelizumab 1 anlotinib 1 Radiotherapy 1 Induction Chemotherapy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Xijing Hospital

Phase NA Unknown

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡